ClinicalTrials.gg
RecruitingNCT07863193Updated Nov 9, 2026

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

A Phase 3 interventional study of Denifanstat and Placebo in Acne Vulgaris, sponsored by Sagimet Biosciences Inc.. Recruiting at 28 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sagimet Biosciences Inc. · Phase 3, Interventional, and Treatment

Updated Nov 9, 2026Start date movedStudy contact changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Planned enrollment
45th of 353
800 · median 78
Started
2026
with 6 others
Phase 3
76 of 373
1 open now
Primary completion
2027-08
later than 23 of 28 live
Registered
371st of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 45th largest by planned enrollment of the 353 interventional ones that give a count, is one of 7 that started in 2026, is one of 76 in phase 3, reaches primary completion later than 23 of the 28 other live ones, and was the 371st registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be willing and able to participate in the trial and provide written or assent
  2. Aged ≥12 years on the date that written informed consent/ assent is provided
  3. Moderate to severe acne vulgaris based on the following criteria at screening:

    1. The EGSS at screening of 3 or 4.

      AND

    2. Number of facial skin lesions:

      • 30 to 75 inflammatory lesions
      • 30 to 100 noninflammatory lesions
  4. All participants with their partners, if any, must agree to the use of an acceptable method of highly effective . Women of (WOCBP) must not be pregnant or breastfeeding, must not plan to become pregnant during the study, and must use 2 forms of birth control, one being a barrier method, or be sexually abstinent.

Exclusion criteria

Exclusion Criteria:

  1. Presence of >2 facial cysts/ nodules
  2. Cystic acne, acne fulminans or acne conglobata
  3. Other significant skin diseases that may affect the efficacy evaluation or require co-treatment
  4. History of dry eye, such as Ocular Surface Disease Index (OSDI) ≥33, or corneal staining ≥ grade III on Oxford Grading Scale, chronic dry eye, or other corneal abnormality
  5. Use of concomitant strong cytochrome P450 (CYP) 3A4 inducers and strong or moderate inhibitors within 2 weeks prior to Day 1 the trial except Paxlovid®
  6. Use of a glucagon-like-peptide 1 (GLP-1) agonist for \<12 weeks prior to first dose of trial medication
  7. Use of any of the following:

    1. Introduction of any drug known to prolong corrected for heart rate (QTC)
    2. Sensitive substrates of P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)
    3. Herbs and supplements such as St John's Wort or grapefruit juice.
  8. Use of concomitant acne treatments unless appropriate is documented
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Denifanstat

    Drug: Denifanstat

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Oral, once daily

  • OtherPlacebo

    Oral, once daily

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline score

    Time frame: Week 12

  2. Absolute change from baseline in inflammatory lesion count (ILC)

    Time frame: Week 12

  3. Absolute change from baseline in non-inflammatory lesion count (ILC)

    Time frame: Week 12

Other outcomes

  1. Safety and tolerability (Open-Label Extension)

    Incidence of treatment-emergent adverse events and serious adverse events; change from baseline in safety parameters

    Time frame: Week 52

07

Study locations

28 of 28 sites recruiting
  • Sagimet Investigative Site
    Bryant, Arkansas 72022, United States
    Recruiting
  • Sagimet Investigative Site
    Beverly Hills, California 90211, United States
    Recruiting
  • Sagimet Investigative Site
    Fremont, California 94538, United States
    Recruiting
  • Sagimet Investigative Site
    San Diego, California 92123, United States
    Recruiting
  • Sagimet Investigative Site
    Santa Ana, California 92705, United States
    Recruiting
  • Sagimet Investigative Site
    Doral, Florida 33126, United States
    Recruiting
  • Sagimet Investigative Site
    Fort Lauderdale, Florida 33308, United States
    Recruiting
  • Sagimet Investigative Site
    Miami, Florida 33125, United States
    Recruiting
  • Sagimet Investigative Site
    Miami, Florida 33126, United States
    Recruiting
  • Sagimet Investigative Site
    Miami, Florida 33175, United States
    Recruiting
  • Sagimet Investigative Site
    Miramar, Florida 33027, United States
    Recruiting
  • Sagimet Investigative Site
    Sweetwater, Florida 33182, United States
    Recruiting
  • Sagimet Investigative Site
    Lincolnshire, Illinois 60069, United States
    Recruiting
  • Sagimet Investigative Site
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Sagimet Investigative Site
    New Albany, Indiana 47150, United States
    Recruiting
  • Sagimet Investigative Site
    Clinton Township, Michigan 48038, United States
    Recruiting
  • Sagimet Investigative Site
    Omaha, Nebraska 68144, United States
    Recruiting
  • Sagimet Investigative Site
    Portsmouth, New Hampshire 03801, United States
    Recruiting
  • Sagimet Investigative Site
    Robbinsville, New Jersey 08691, United States
    Recruiting
  • Sagimet Investigative Site
    Wilmington, North Carolina 28045, United States
    Recruiting
  • Sagimet Investigative Site
    Columbus, Ohio 43215, United States
    Recruiting
  • Sagimet Investigative Site
    East Greenwich, Rhode Island 02818, United States
    Recruiting
  • Sagimet Investigative Site
    Greenville, South Carolina 29615, United States
    Recruiting
  • Sagimet Investigative Site
    Murfreesboro, Tennessee 37130, United States
    Recruiting
  • Sagimet Investigative Site
    Nashville, Tennessee 37215, United States
    Recruiting
  • Sagimet Investigative Site
    College Station, Texas 77845, United States
    Recruiting
  • Sagimet Investigative Site
    El Paso, Texas 79902, United States
    Recruiting
  • Sagimet Investigative Site
    Spokane, Washington 99202, United States
    Recruiting
08

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's planned 10 months is below that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartActual
Oct 21, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Apr 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added
Show 24 added (24 United States)
  • Sagimet Investigative Site · Santa Ana, United States
  • Sagimet Investigative Site · Fort Lauderdale, United States
  • Sagimet Investigative Site · Miami, United States
  • Sagimet Investigative Site · Miami, United States
  • Sagimet Investigative Site · Miramar, United States
  • Sagimet Investigative Site · Indianapolis, United States
  • Sagimet Investigative Site · New Albany, United States
  • Sagimet Investigative Site · Clinton Township, United States
  • Sagimet Investigative Site · Portsmouth, United States
  • Sagimet Investigative Site · Wilmington, United States
  • Sagimet Investigative Site · East Greenwich, United States
  • Sagimet Investigative Site · Greenville, United States
  • Sagimet Investigative Site · Murfreesboro, United States
  • Sagimet Investigative Site · College Station, United States
  • Sagimet Investigative Site · El Paso, United States
  • Sagimet Investigative Site · Spokane, United States
  • Sagimet Investigative Site · Lincolnshire, United States
  • Sagimet Investigative Site · Columbus, United States
  • Sagimet Investigative Site · Nashville, United States
  • Sagimet Investigative Site · Beverly Hills, United States
  • Sagimet Investigative Site · San Diego, United States
  • Sagimet Investigative Site · Sweetwater, United States
  • Sagimet Investigative Site · Omaha, United States
  • Sagimet Investigative Site · Robbinsville, United States
across 3 updates, Oct 23, 2026 – Nov 5, 2026
Start date
Oct 1, 2026→Oct 21, 2026
Nov 9, 2026
Contact
Study contact's phone or email changed: none listed→c•••@sagimet.com. See the current contact
Nov 5, 2026
Title
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Oct 22, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 6 updates
  1. Nov 9, 2026
    Start date Oct 1, 2026→Oct 21, 2026
    + 1 other change: verification date
  2. Nov 5, 2026
    5 sites added
    Show 5 added (5 United States)
    • Sagimet Investigative Site · Beverly Hills, United States
    • Sagimet Investigative Site · San Diego, United States
    • Sagimet Investigative Site · Sweetwater, United States
    • Sagimet Investigative Site · Omaha, United States
    • Sagimet Investigative Site · Robbinsville, United States
    Contact Study contact's phone or email changed: none listed→c•••@sagimet.com. See the current contact
    + 1 other change: date precision
  3. Oct 29, 2026
    3 sites added
    Show 3 added (3 United States)
    • Sagimet Investigative Site · Lincolnshire, United States
    • Sagimet Investigative Site · Columbus, United States
    • Sagimet Investigative Site · Nashville, United States
  4. Oct 23, 2026
    16 sites added
    Show 16 added (16 United States)
    • Sagimet Investigative Site · Santa Ana, United States
    • Sagimet Investigative Site · Fort Lauderdale, United States
    • Sagimet Investigative Site · Miami, United States
    • Sagimet Investigative Site · Miami, United States
    • Sagimet Investigative Site · Miramar, United States
    • Sagimet Investigative Site · Indianapolis, United States
    • Sagimet Investigative Site · New Albany, United States
    • Sagimet Investigative Site · Clinton Township, United States
    • Sagimet Investigative Site · Portsmouth, United States
    • Sagimet Investigative Site · Wilmington, United States
    • Sagimet Investigative Site · East Greenwich, United States
    • Sagimet Investigative Site · Greenville, United States
    • Sagimet Investigative Site · Murfreesboro, United States
    • Sagimet Investigative Site · College Station, United States
    • Sagimet Investigative Site · El Paso, United States
    • Sagimet Investigative Site · Spokane, United States
  5. Oct 22, 2026
    Title Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
  6. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07863193
Lead sponsor
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 21, 2026
Primary completion
Aug 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Study Director
Contact
clinicalhotline@sagimet.com
(650) 561-8675

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion